JamJoom Pharmaceuticals Kept at Neutral as AlJazira Capital Notes Q2 Results

05:59 AM EDT, 08/27/2026 (MT Newswires) -- AlJazira Capital reiterated its neutral rating on JamJoom Pharmaceuticals Factory Co (SASE:4015) as it took note of the company's second-quarter results and long-term growth prospects. "While structural demand across its core therapeutic areas, disciplined capital allocation and strong profitability should continue to support healthy long-term growth, we believe these strengths are largely reflected in the current valuation. We forecast revenue and net profit CAGRs of 9.2% and 8.2%, respectively, over FY25-30E, while maintaining healthy margins despite a gradual shift towards vaccines and biosimilars from FY28 onwards," analysts wrote Wednesday in a report focused on the Saudi Arabia pharmaceutical sector. For the second quarter, the pharmaceutical company logged a 4.2% year-over-year increase in net profit to 138 million Saudi riyals. Meanwhile, revenue rose 12.4% annually to 445 million riyals. The stock has a price target of 144.9 riyals at AlJazira Capital.